Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer

Bagheri, Elnaz; Abnous, Khalil; Farzad, Sara Amel; Taghdisi, Seyed Mohammad; Ramezani, Mohammad; Alibolandi, Mona

doi:10.1016/j.lfs.2020.118369

Cited by 142 publications

(74 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, investigations in MCF-7 breast tumor xenograft models indicated that hUC-MSC-Tf-inspired NPs could potently abrogate tumor growth, bringing novel anticancer drug delivery approach ( Cao et al, 2018 ). Remarkably, other reports have shown that injection of DOX-loaded exosomes (Exo) derived from MSCs into an ectopic model of C26 (mouse colon adenocarcinoma) in BALB/c mice could support suppressed tumor growth in treated animals compared with those injected with DOX alone ( Bagheri et al, 2020 ). On the other hand, biomimetic nanovesicles derived from human-induced pluripotent stem cells (iPSCs)-derived MSCs loaded with DOX demonstrated more notable cytotoxic effects on doxorubicin-resistant triple-negative breast cancer (TNBC) cells, and also robustly reduced the occurrence and burden of metastases in murine models of TNBC in comparison with the free or liposomal doxorubicin application ( Zhao et al, 2020 ).…”

Section: Msc-based Chemotherapeutic Agent Deliverymentioning

confidence: 99%

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

Hassanzadeh

Altajer²,

Rahman

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stem/stromal cell (MSC)-based therapy has become an attractive and advanced scientific research area in the context of cancer therapy. This interest is closely linked to the MSC-marked tropism for tumors, suggesting them as a rational and effective vehicle for drug delivery for both hematological and solid malignancies. Nonetheless, the therapeutic application of the MSCs in human tumors is still controversial because of the induction of several signaling pathways largely contributing to tumor progression and metastasis. In spite of some evidence supporting that MSCs may sustain cancer pathogenesis, increasing proofs have indicated the suppressive influences of MSCs on tumor cells. During the last years, a myriad of preclinical and some clinical studies have been carried out or are ongoing to address the safety and efficacy of the MSC-based delivery of therapeutic agents in diverse types of malignancies. A large number of studies have focused on the MSC application as delivery vehicles for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), chemotherapeutic drug such as gemcitabine (GCB), paclitaxel (PTX), and doxorubicin (DOX), prodrugs such as 5-fluorocytosine (5-FC) and ganciclovir (GCV), and immune cell-activating cytokines along with oncolytic virus. In the current review, we evaluate the latest findings rendering the potential of MSCs to be employed as potent gene/drug delivery vehicle for inducing tumor regression with a special focus on the in vivo reports performed during the last two decades.

show abstract

Section: Msc-based Chemotherapeutic Agent Deliverymentioning

confidence: 99%

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

Hassanzadeh

Altajer²,

Rahman

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Greco et al demonstrated that MSC-EVs offer some benefits in comparison to normal cells, because they can be internalized by cancer cells to a greater percentage than normal cells [70]. Additionally, EVs are smaller and have been shown to be less immunogenic than MSCs, which is why they are able to carry chemotherapeutics such as paclitaxel [71] or doxorubicin [72] as well as anti-tumor RNA-based therapeutics such as different miRNAs [73][74][75][76][77][78]. However, MSCs might also possess a negative regulatory capacity in cancer treatment.…”

Section: Mscs In Cancermentioning

confidence: 99%

The Role of MSCs and Cell Fusion in Tissue Regeneration

Dörnen

Dittmar

2021

IJMS

View full text Add to dashboard Cite

Regenerative medicine is concerned with the investigation of therapeutic agents that can be used to promote the process of regeneration after injury or in different diseases. Mesenchymal stem/stromal cells (MSCs) and their secretome – including extracellular vesicles (EVs) are of great interest, due to their role in tissue regeneration, immunomodulatory capacity and low immunogenicity. So far, clinical studies are not very conclusive as they show conflicting efficacies regarding the use of MSCs. An additional process possibly involved in regeneration might be cell fusion. This process occurs in both a physiological and a pathophysiological context and can be affected by immune response due to inflammation. In this review the role of MSCs and cell fusion in tissue regeneration is discussed.

show abstract

“…Although some cell-culture-derived EVs have shown certain therapeutic effects, including tissue repair [ 19 , 20 , 26 ], they have limited biological activities in most cases. Thus, the engineering of EVs by encapsulating pharmaceutical drugs, such as miRNA, chemicals, peptides, and proteins into EVs, is required to endow their therapeutic activities [ 27 , 28 , 29 , 30 ]. Furthermore, mammalian cell cultures accompany the use of animal-derived materials, including fetal bovine serum, which is commonly prohibited in drug approval, due to safety issues.…”

Section: Introductionmentioning

confidence: 99%

Antioxidative Effects of Carrot-Derived Nanovesicles in Cardiomyoblast and Neuroblastoma Cells

Kim

Rhee

2021

Pharmaceutics

View full text Add to dashboard Cite

Oxidative stress is implicated in many diseases, including cardiovascular and neurodegenerative diseases. Because an increased level of oxidative stress causes apoptosis, it is necessary to inhibit cellular responses to oxidative stress. In this study, Carex, a nanovesicle from carrot, was isolated and investigated as a novel biomaterial with antioxidative function in cardiomyoblasts and neuroblastoma cells. A high concentration of nanovesicles was purified from carrots, using size-exclusion chromatography in combination with ultrafiltration. The characterization of Carex demonstrated that it had properties similar to those of extracellular vesicles. Carex showed low cytotoxicity in both H9C2 cardiomyoblasts and SH-SY5Y neuroblastoma cells, when a high level of Carex was delivered to the cells. Carex was further investigated for its antioxidative and apoptotic effects, and it significantly inhibited ROS generation and apoptosis in vitro in myocardial infarction and Parkinson’s disease models. Carex inhibited the reduction of antioxidative molecule expression, including Nrf-2, HO-1, and NQO-1, in both models. Considering its antioxidative function and high production yield, Carex is a potential drug candidate for the treatment of myocardial infarction as well as Parkinson’s disease. Thus, the results demonstrated in this study will contribute to an exploration of a novel drug, using nanovesicles from plants, including carrots.

show abstract

Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer

Cited by 142 publications

References 39 publications

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy

The Role of MSCs and Cell Fusion in Tissue Regeneration

Antioxidative Effects of Carrot-Derived Nanovesicles in Cardiomyoblast and Neuroblastoma Cells

Contact Info

Product

Resources

About